Dna X (SONM) EBITDA (2018 - 2026)

Dna X's EBITDA history runs 9 years deep, the most recent figure standing at -$3.6 million for Q1 2026.

• Quarterly EBITDA fell 315.86% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.7 million (down 654.8% YoY) and the FY2025 annual result came in at -$5.4 million, down 74.39% from the prior year.
• EBITDA was -$3.6 million for Q1 2026 at Dna X, down from $4.7 million in the prior quarter.
• Across five years, EBITDA topped out at $8.4 million in Q4 2024 and bottomed at -$7.1 million in Q1 2022.
• A 5-year average of -$1.6 million and a median of -$1.9 million in 2022 frame the typical range for EBITDA.
• Peak annual rise in EBITDA reached 772.11% in 2024, while the deepest fall reached 966.13% in 2024.
• Dna X's EBITDA stood at -$1.1 million in 2022, then fell by 18.51% to -$1.3 million in 2023, then jumped by 772.11% to $8.4 million in 2024, then tumbled by 44.74% to $4.7 million in 2025, then plunged by 177.62% to -$3.6 million in 2026.
• Business Quant data shows SONM's EBITDA at -$3.6 million in Q1 2026, $4.7 million in Q4 2025, and -$4.0 million in Q3 2025.